News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Curis, Inc. Reports First Quarter 2009 Financial Results
May 5, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today reported its financial results for the quarter ended March 31, 2009.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Curis, Inc.
MORE ON THIS TOPIC
China
Deerfield bets up to $1.6B to snag autoimmune asset in China for Boulevard
June 30, 2026
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
Zymeworks adds lung disease drug, royalty deals in nearly $1B pick up of Theravance
June 29, 2026
·
2 min read
·
Annalee Armstrong
Pipeline
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
June 26, 2026
·
2 min read
·
Tristan Manalac
M&A
Merck KGaA inks $11B Bio-Techne buyout to expand into cell therapy production
June 26, 2026
·
2 min read
·
Nick Paul Taylor
